Here's Why You Should Retain INSP Stock in Your Portfolio for Now

Inspire Medical Systems is building momentum around its fifth-generation Inspire V system with expanding clinical evidence and improving reimbursement clarity across all six WISeR states. However, Q2 revenues declined 7.6% to $200.6M due to persistent coding disruption, and GLP-1 therapy adoption poses a risk to near-term procedure volumes. The company faces execution risks in translating patient-flow initiatives into sustained growth.